Market Access Manager
in health
A Market Access Manager wins funding and procurement for a therapy or device across the NHS pharma and life sciences so it actually reaches patients.
A Market Access Manager turns clinical and economic value into funded, real-world use. In plain terms, they make sure a medicine, device, diagnostic, or tech-enabled service can be paid for, procured, and adopted by the health systems it targets, without bending the evidence or cutting compliance corners.
The role exists because building something that works is not the same as getting it used at scale. The NHS runs on constrained budgets, formal decision pathways, and a high bar of proof. A pharma company can have a strong Phase III readout and still face a NICE appraisal that questions cost-effectiveness. A device maker can clear the regulator and still stall in NHS Supply Chain procurement. The Market Access Manager owns the strategy that bridges product capability and payer decision-making: what claims hold up, what outcomes must be proven, what blocks uptake, and what commercial model survives scrutiny.
At its best this is not a support function or a document factory. It is ownership of a business-critical outcome: dependable routes to reimbursement, procurement, and sustained adoption, while protecting the organisation from avoidable access risk.
How this role differs across the sector
Market access looks different depending on where you sit, and the honest version of this role respects that.
In pharma and biotech, the centre of gravity is health technology assessment. You build the value dossier for NICE (or the SMC in Scotland and the AWMSG in Wales), you defend the cost-effectiveness case, and you shape the commercial agreement (patient access schemes, confidential discounts, outcomes-based deals) that lets a treatment be reimbursed. The evidence burden is heavy and the timelines are long.
In medical devices and diagnostics, the work tilts towards NHS procurement, tariff and coding, and local business cases. A product can be clinically excellent and still need a clear story on budget impact, pathway change, and who holds the money. NICE routes here include the medtech and diagnostics programmes, which behave differently from the medicines appraisal.
In digital health and HealthTech, access is also a governance problem. Decisions are shaped by public accountability, patient safety expectations, clinical workflow reality, data assurance (DTAC, the NICE evidence standards framework for digital health), and a higher bar around outcomes than most consumer tech ever faces. You cannot iterate on promises made to a commissioner the way a growth team iterates on a funnel.
In contract research and consulting, a market access professional often advises several clients at once on HEOR, value communication, or pricing, rather than carrying one product through to a reimbursement decision.
The common thread: across all of these, access work is more constrained and therefore more strategic than a typical go-to-market role. A procurement or appraisal win can still fail if implementation is underestimated, the evidence does not translate to the real setting, or the commercial model clashes with how health budgets are held.
Core responsibilities of a Market Access Manager
Day to day, a Market Access Manager carries accountability for the access plan: which segments or systems to target first, what the fundable story is, and what must be true (in evidence, economics, and implementation) for a payer or commissioner to say yes.
- Build the access strategy: define target segments, sequencing, and the value proposition that survives formal assessment and procurement.
- Lead or shape the HTA submission: assemble the evidence and economic case for NICE, the SMC, or the AWMSG, and respond to challenge during appraisal.
- Translate clinical impact into economic terms: budget impact, cost-effectiveness, and opportunity cost in the real service context, working with health economics and HEOR colleagues.
- Design the commercial model: pricing, patient access schemes, risk-sharing, and outcomes-based terms that can be bought, renewed, and defended.
- Engage payers and decision-makers: national bodies, integrated care boards, NHS procurement, clinical leads, and (where relevant) private healthcare and insurer buyers.
- Hold the evidentiary line internally: decide what claims can be substantiated when commercial or clinical colleagues want bolder messaging.
- Plan for implementation: account for pathway change, training burden, data flows, and the operational friction that quietly kills adoption.
- Track the market and flag risk: watch policy shifts, comparator launches, and procurement timelines that change the plan.
They make trade-offs under real constraints. If the ideal evidence package takes too long, they decide the minimum credible package that gets a pilot moving without damaging long-term positioning. If a pricing model maximises revenue but creates procurement friction, they reshape the offer so it can be bought and renewed.
Organisationally, the role usually sits within Commercial, Strategy, or a combined Market Access, Pricing, and HEOR function, working closely with Medical and Clinical, Regulatory and Quality, Product, and Sales. In a lean biotech, medtech, or scale-up it can be a team-of-one role with outsized influence, because access constraints often define what the business can realistically scale.
Skills and competencies for the role
| Core skill | What it means in this sector | Why it matters |
|---|---|---|
| Payer and system judgement | Reading how health decisions get made across national bodies (NICE, SMC, AWMSG), integrated care boards, NHS procurement, and local clinical leads, including who holds budget and who owns risk | Prevents building an unbuyable proposition and stops time being lost on the wrong decision pathway |
| HTA and submission literacy | Understanding the appraisal routes that apply to your product (medicines, medtech, diagnostics, digital health) and what evidence each demands | A strong dossier that fits the right process is the difference between reimbursement and rejection |
| Health economics and affordability | Translating clinical impact into budget impact and cost-effectiveness, and partnering with HEOR on models | Funding conversations turn on economics, not enthusiasm; a credible case feels feasible rather than theoretical |
| Value storytelling with evidentiary discipline | Framing outcomes so they are compelling but defensible under assessment and procurement scrutiny | Protects credibility, avoids rework, and helps adoption survive past the first pilot |
| Negotiation and contracting | Knowing which terms matter (discounts, risk-sharing, outcomes, service levels) and what to concede | Drives durable deals rather than headline wins that collapse at rollout or renewal |
| Implementation-aware strategy | Designing access plans that account for pathway change, training, data flows, and operational load | In health systems, adoption fails more often on delivery friction than on the concept itself |
| Compliance and ethics mindset | Decisions that respect the ABPI Code (for medicines), governance, and transparency expectations | Reduces reputational and commercial risk in a sector where trust is a growth limiter |
Salary ranges in the UK
Pay tracks the size of the access problem you personally own. The biggest drivers are whether you lead national or regional strategy, whether you carry launch or HTA accountability, the complexity of the evidence and pricing, how scrutinised the category is, and whether you work solo or manage a team. Setting matters too: large pharma and medtech tend to pay more than early-stage biotech or digital health, though equity can close the gap. Location still matters, but seniority and scope usually matter more than geography.
| Experience level | Estimated annual salary range | What drives compensation |
|---|---|---|
| Junior | London & South East: £45k to £58k. Rest of UK: £42k to £54k | Entry into access work (often with support), narrower ownership, limited exposure to negotiation and high-stakes submissions |
| Mid-level | London & South East: £60k to £82k. Rest of UK: £55k to £75k | Owning defined workstreams (one product or therapy area), direct payer engagement, responsibility for value materials and cross-functional alignment |
| Senior | London & South East: £82k to £105k. Rest of UK: £75k to £98k | Leading access or HTA strategy for a product line or region, higher autonomy, launch accountability, real judgement under constraint |
| Lead | London & South East: £100k to £125k. Rest of UK: £92k to £115k | Portfolio ownership, formal leadership of strategy and execution, line management in some teams, accountability for outcomes |
| Head / Director | London & South East: £125k to £175k. Rest of UK: £115k to £160k | Function leadership, cross-market strategy, pricing governance, executive stakeholder management, responsibility for access risk across the business |
Sources: Glassdoor UK (average base around £68k, typical total pay £68k to £103k, with senior submissions reaching £97k base plus bonus), Indeed UK and LinkedIn listings, and published life sciences recruitment salary guides (Hays, EPM Scientific). Treat these as a guide; real offers move with employer, setting and specialism.
Beyond base, total compensation commonly includes an annual bonus (often tied to access milestones, launch goals, or company performance), and in venture-backed biotech or HealthTech, equity or options are more likely than in larger employers. Higher packages show up where the role carries international scope, pricing governance, heavy travel, or a build-the-function mandate where failure would block revenue.
Career pathways
Many Market Access Managers arrive from adjacent foundations: health economics, HEOR, policy, NHS commissioning or procurement, pricing or reimbursement roles, consulting, or commercial operations in pharma and medtech. Others move internally from medical affairs, customer success, or implementation once they understand what blocks adoption and what decision-makers actually need to fund scale. A scientific or clinical degree helps, and many teams value a master's in health economics, public health, or a life science.
Progression is an expansion of ownership rather than a straight ladder. Early on you may own value materials and pieces of the strategy. Later you own it end to end and carry the consequence when access assumptions are wrong. The step to senior often happens when you can run payer engagement independently, defend the value story under challenge, and balance credibility, speed, and commercial viability. Lead and Head roles are defined by portfolio accountability: you set direction, establish standards, and stop local wins from creating long-term risk. From there, routes open into commercial leadership, general management, or a Chief Commercial role in a smaller company.
FAQ
Do I need a health economics background to get hired as a Market Access Manager? Not always, but you do need credibility on affordability and value. Many teams accept a strong payer-facing profile if you can partner well with HEOR specialists. You will be assessed on whether you can hold an evidence-based line under challenge, not on whether you can build every model yourself.
What does a good market access outcome look like beyond getting a pilot? Funded adoption that survives rollout: a clear decision rationale, a buyable commercial model, and implementation commitments that do not collapse in practice. Interviewers look for signs you can turn interest into a repeatable pathway rather than one-off exceptions.
How much does the work change between pharma and digital health? A lot. In pharma the core skill is the NICE or SMC appraisal and the pricing agreement behind it. In digital health you spend more time on procurement, commissioning, and assurance frameworks like DTAC, often with thinner evidence and faster cycles. Devices and diagnostics sit between the two. The transferable core is reading the system, building the economic case, and protecting credibility.
Is there on-call for Market Access Managers? Uncommon in the classic sense, but expect intense periods around submission deadlines, contracting milestones, or launch readiness. If a role is closely tied to bids or HTA timelines you may face urgent turnaround without a formal rota. It is reasonable to ask how often that happens and what support exists.
Find your next role
Search Market Access Manager roles on Meeveem to find pharma, medtech, diagnostics, and digital health teams where access ownership is clear, resourced, and tied to real adoption outcomes.